Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
about
Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding siteStructural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.Impact of OATP transporters on pharmacokinetics.Cytochrome P450 2C8 pharmacogenetics: a review of clinical studiesPharmacogenetics in drug regulation: promise, potential and pitfalls.The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsLack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.Effect of rifampicin on the pharmacokinetics of pioglitazoneThe impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideThe effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.Fluvastatin and fluvastatin extended release: a clinical and safety profile.Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.Lipid-lowering drugs.Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liverDetection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media.Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.Role of OATP transporters in the disposition of drugs.Interaction between statins and clopidogrel: is there anything clinically relevant?Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.2D QSAR Study for Gemfibrozil Glucuronide as the Mechanism-based Inhibitor of CYP2C8.Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.Transporter-mediated drug-drug interactions.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Drug interactions with statins.Statin intolerance: diagnosis and remedies.Effect of gemfibrozil or rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
P2860
Q27642793-4CDAB253-AA13-4AF4-B396-3BD71608FC7BQ30396630-1C52A3C6-B50D-4C38-B816-6C4A887DC63AQ34561039-C6908E78-E484-4D5E-9A7D-DFB1B9734698Q34612244-4186565D-5CE3-4039-BE35-ED66C1AF5EE1Q35003605-2E0C78AA-24F4-4C28-A1C4-5F7C4D2BC493Q35038052-30679B2B-9BD7-43BA-84BD-802D9165FDBFQ35826014-272B1F4C-1457-4C2F-90CC-6165611C1D22Q35826433-4142B9A6-CA15-4AE7-BA51-63546BD45F3AQ35826894-6B719878-1B13-4E80-B587-0558850C4474Q35827146-BDFEF9A3-FCA3-408A-A67A-A90B412D37CDQ35827269-68DE4A71-E5F6-43BD-B73F-6639CD269F62Q35827325-2F1784BF-9274-45E8-8539-3EFC62F5071EQ35827353-08F8C884-647B-431E-9779-5511627ACBF6Q35827882-EFFAEA59-6614-4505-8D12-86CB980158F6Q35827919-A36E1B2C-F89F-4454-83A6-C53F553686B4Q35879055-349EBA6C-16A1-412F-9490-8E7204F364B3Q35925640-BB66DBE0-113B-468C-A441-9B5231AAE6CBQ36002780-08227ECE-90F1-42DE-B90B-706A24947AC2Q36040772-BFBD41C9-9BCF-48FE-92A6-0BD05F2F0D3FQ36174736-7C79B724-05D1-4153-B5CD-0C5958685D49Q36320218-B7BD07D6-930D-4880-B59C-DC27337E1EAFQ36349758-4EE9C091-6281-4708-9BD7-ED7FD3F38E2AQ36544966-5C4067B4-E660-4573-B04E-B750DE801A9DQ36562502-5A85EBE0-6737-4516-8773-91FAB09A79FEQ37074085-7FFC14CD-5163-494E-B1D7-B8AA9A54152BQ37234094-4BF45637-92C8-4757-AEF0-2A67B5C391D9Q37473376-E649770D-53E2-44A9-A113-4D7E2BFE0D94Q37481450-C87A956C-C0C7-43FA-899F-02D99F75D2E1Q37592433-200D1092-67EE-478C-BC59-0CEA0E64DBEBQ37680968-BC0038BE-C369-4C49-9A4B-3831DF9AAB24Q37845170-D8E17CEB-C9B7-442B-B076-92A94DD0E8EAQ37905033-2F5B4762-0003-49B4-823B-2378D19AE3DDQ37960129-AB820F90-CE8C-437A-8495-030BB27821D1Q37986145-CED3520A-6CED-4570-A179-E0324EB25A7CQ38130410-4AE33744-62D8-44CE-9A6B-8B0BF73FF926Q38155016-909C969C-3FCA-4BA8-9C76-A60A206415D2Q38430744-72A1DBE1-0121-4BDA-ABB6-2BE76199C1E7Q38675399-BFE9ED7D-DC87-4ACF-BCB4-69C31030ACD3Q38684505-25C8B99F-DDCF-4CE6-AEBC-CC863B82225DQ38933872-7591C22C-96F9-4EF5-A9B0-90181B85A080
P2860
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@ast
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@en
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@nl
type
label
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@ast
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@en
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@nl
prefLabel
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@ast
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@en
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@nl
P2093
P356
P1476
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
@en
P2093
Janne T Backman
Jun-Sheng Wang
Mikko Neuvonen
Pertti J Neuvonen
P304
P356
10.1124/DMD.30.12.1352
P577
2002-12-01T00:00:00Z